Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
altSonflex1-2-3 Shigella Vaccine in African Infants
NCT06663436Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of altSonflex1-2-3 in shigellosis, sponsored by GSK. Started Nov 2024; status: completed.
02
Drugs
altSonflex1-2-3
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT06663436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663436.